Business Information
The group's principal activity is to discover, develop and market pharmaceuticals for treatment of cancer and inflammatory diseases. Its primary focus is on the development of orally administered, small molecule pharmaceuticals that regulate gene and protein modulation. Thalomid, the group's lead product is evaluated in clinical trials for the treatment of solid tumor and hematological cancers as well as serious inflammatory diseases. The drugs are designed to modulate multiple disease-related genes, tnf (alpha) and anti-angiogenic. Tnf (alpha) has been linked to the cause and symptoms of many chronic inflammatory and immunological diseases. Anti-angiogenic drugs inhibit the growth of undesirable blood vessels, including those that promote tumor growth.
|
|
Name |
Title
|
Email
|
| Sol Barer | Chmn., CEO | N/A | | David Gryska | CFO | N/A | | Robert Hugin | Dir., CFO, COO, Pres., Sr. VP | N/A | | Arthur Hayes | Dir. | N/A | | Ernest Mario | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 898,873 | 68,981 | | 2005 | 536,941 | 63,656 | | 2004 | 377,502 | 52,756
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
